Bradley Merrill Thompson, a Member of the Firm in the Health Care and Life Sciences practice, in the firm’s Washington, DC, office, was quoted in Fast Company, in “Feds: Theranos’s Deficiencies Put Patient Safety in ‘Immediate Jeopardy,’” by Christina Farr.
Following is an excerpt:
Experts say the consequences will be serious if Theranos doesn’t take immediate action to alleviate CMS’s concerns.
“If CMS revokes their license, at a minimum that makes it challenging to get reimbursement for the tests they perform,” says Bradley Merrill Thompson, a health policy expert and lawyer with the firm Epstein, Becker & Green. “They really need to correct the issues quickly.”